Ignite Creation Date:
2024-05-05 @ 6:53 PM
Last Modification Date:
2024-10-26 @ 9:38 AM
Study NCT ID:
NCT00564759
Status:
UNKNOWN
Last Update Posted:
2007-11-28
First Post:
2007-11-26
Brief Title:
Gene Therapy for Chronic Granulomatous Disease
Sponsor:
Johann Wolfgang Goethe University Hospital
Organization:
Johann Wolfgang Goethe University Hospital
Study Overview
Official Title:
Phase III Gene Therapy Study for X-Linked Chronic Granulomatous Disease
Status:
UNKNOWN
Status Verified Date:
2007-11
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CGD
Brief Summary:
The aim of the study is to evaluate the side effects and risks after infusion of retroviral gene corrected autologous CD34 cells of the peripheral blood of chemotherapy conditioned busulphanpatients with chronic granulomatous disease CGD Also gene corrected and functional active granulocytes in the peripheral blood and the engraftment in the bone marrow of the patients will be monitored an documented
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DeReG 31 | None | None | None |
| KSG 31 | None | None | None |